Kenvue Faces Sharp Downturn Amid Regulatory Concerns

about 1 month ago

Nathan Hager

"Kenview shares are down over 4.5% in pre-market here, Nathan. This comes after a Washington Post article that the Trump administration plans to link the active ingredient in Tylenol to autism. Now, officials plan to warn pregnant women against using the medication while pregnant."

Kenvue, the maker of Tylenol, is experiencing significant share declines (over 15% drop recently) following regulatory signals linking its active ingredient to autism. The news serves as a negative catalyst, suggesting caution or a potential short position for investors.